Solid Tumors
Conditions
Interventions
investigational material(s)
Generic name etc : LY2603618
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational materia
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Have histological or cytological or imaging evidence of a diagnosis of cancer that is advanced and/or metastatic disease - Patient who is planned to have gemcitabine therapy at the proposed doses because he/she was not able to benefit from standard therapy and/or therapies known to provide clinical benefit or there is no standard therapy for the advanced and/or metastatic disease globally - Have adequate organ function - Have a performance status of 0-2 on the ECOG scale - Have discontinued all previous therapies for cancer, including chemotherapy,cancer-related hormonal therapy, or other investigational therapy for at least 30 days (42 days for mitomycin C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy - Prior radiation therapy for treatment of cancer is allowed to less than 25% of the bone marrow, and patients must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 30 days prior to study enrollment - Have an estimated life expectancy of at least 12 weeks
Exclusion criteria
Exclusion criteria:
Outcome results
None listed